<DOC>
	<DOCNO>NCT02792647</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability IX-01 multiple dos , determine PK IX-01 activity CYP3A4 .</brief_summary>
	<brief_title>A Study Multiple Oral Doses IX-01 Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Male healthy volunteer . 2 . Aged 1845 year time signing informed consent . 3 . A body mass index ( Quetelet index ) range 1830 . 4 . Total body weight &gt; 50 kg screening . 5 . Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily investigator participate , comply requirement , entire trial . 6 . Willingness comply contraception requirement trial . 7 . Willingness give write consent participate reading information consent form , opportunity discuss trial investigator delegate . 8 . Willingness give write consent data enter The Overvolunteering Prevention System ( TOPS ) . 1 . Clinically relevant abnormal history , physical finding , ECG , laboratory value pretrial screening assessment could interfere objective trial safety volunteer , include follow finding : lipid and/or liver function test result &gt; 1.25 x ULN clinical laboratory blood biochemistry test result outside normal reference range unless discuss approve sponsor history unexplained syncope family history unexplained sudden death , sudden death due long QT syndrome QTcF interval &gt; 450 msec 2 3 consecutive ECGs ( additional ECGs may record , require , median QTcF â‰¤ 450 msec 3 consecutive ECGs require volunteer consider eligible ) bundle branch block conduction abnormality , mild first degree atrioventricular block irregular rhythm sinus arrhythmia occasional supraventricular ectopic beat Twave configuration insufficient quality determination QT interval , assess investigator 2 . Presence acute chronic illness history chronic illness sufficient invalidate volunteer 's participation trial make unnecessarily hazardous . 3 . Impaired gastrointestinal , endocrine , thyroid , hepatic , cardiovascular , respiratory , haematological , renal neurological function , diabetes mellitus , coronary heart disease , history psychotic mental illness . 4 . Surgery ( e.g . stomach bypass ) medical condition might affect absorption medicine . 5 . Presence history severe adverse reaction drug . 6 . Use prescription overthecounter medicine 14 day first dose trial medication , intention use medicine trial , exception short course medication consider investigator interfere safety subject integrity trial data ( acetaminophen ( paracetamol ) ) . 7 . Current use herbal remedy nutritional supplement , intention use product study . 8 . Participation another clinical trial new chemical entity prescription medicine within 3 month prior first dose . 9 . Previous participation trial clinical trial oxytocin receptor antagonist . 10 . Presence history drug alcohol abuse , intake 21 unit alcohol weekly 5 cigarette daily . 11 . Blood pressure heart rate supine position screen examination outside range 90130 mm Hg systolic , 5090 mm Hg diastolic ; heart rate 5090 beats/min , unless judge clinically significant investigator . 12 . Possibility volunteer cooperate requirement protocol . 13 . Evidence drug abuse urine testing . 14 . Positive test hepatitis B , hepatitis C HIV1 HIV2 . 15 . Loss 400 mL blood 3 month prior first dose , eg blood donor . 16 . Objection General Practitioner ( GP ) volunteer enter trial . 17 . Employee investigator site company involve sponsoring , organise conduct trial , immediate family employee . Immediate family define spouse , parent , child sibling , whether biologically relate legally adopt .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>